Elusys Therapeutics Inc.
Boca Raton, FL
- UEI
- ELP1DCK8L191
- CAGE
- 1WEK8
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Nighthawk Biosciences, Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 7700 Congress Ave #2207, Boca Raton, FL 33487, USA
- Website
- elusys.com
- Founded
- 1998
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $55,273,060 |
| FY2024 | $68,664,856 |
| FY2023 | -$830,800 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Anthim (OBILTOXAXIMAB) | Office of the Assistant Secretary for Preparedness and Response | $124,523,123 | |
| Anthim letter contract | Office of the Assistant Secretary for Preparedness and Response | $79,947,200 | |
| For other functions | Office of the Assistant Secretary for Preparedness and Response | $24,501,100 | |
| For other functions | Office of the Assistant Secretary for Preparedness and Response | $44,971,900 | |
| Anthim IM and stability testing | ACC Redstone | $734,898 |
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Heteropolymer antibody technology-development of our heteropolymer antibody technology against anthrax and other… | Department of the Army | $888,000 |
Similar vendors
About the company
Products and Services
The government contractor appears to specialize in biomedical research and development, with a focus on advanced technology. The products and services provided include "ANTHIM LETTER CONTRACT", "FOR OTHER FUNCTIONS", "BIOMEDICAL (ADVANCED)", and "BIOMEDICAL (BASIC)". Over time, the contractor has shifted from basic biomedical services to more advanced and specific contracts, such as the "ANTHIM" contracts.
Customers
The primary agencies awarding contracts to this contractor are the Department of Health and Human Services (HHS), the Department of Defense (DOD) - Army - AMC - ACC, HHS - NIH, and DOD - Navy - SECNAV. Over time, the contractor has expanded its customer base from the DOD to include HHS and NIH. The top buyers from this contractor are HHS and DOD, with HHS being the most frequent buyer.
Vehicles
The contract vehicles awarded to this contractor include Definitive Contracts and Delivery Orders. Over time, the contractor has maintained a balance between these two types of contracts, with a slight increase in Definitive Contracts.
Summary
The government contractor has a strong history of contract awards, primarily in the biomedical research and development sector. The contractor has successfully expanded its customer base over time, and has maintained a balance between Definitive Contracts and Delivery Orders. The contractor's focus on advanced biomedical services suggests a commitment to innovation and technological advancement.
Data
The analysis is based on seven contracts awarded between 09/28/04 and 08/06/21.
Quick answers
Is Elusys Therapeutics Inc. registered in SAM.gov?
Yes. Elusys Therapeutics Inc.'s SAM.gov registration is active through March 12, 2027.
What is Elusys Therapeutics Inc.'s CAGE code?
Elusys Therapeutics Inc.'s CAGE code is 1WEK8, and its Unique Entity ID (UEI) is ELP1DCK8L191.
How much has Elusys Therapeutics Inc. received in federal contracts?
Federal contracts obligated $55,273,060 to Elusys Therapeutics Inc. in fiscal year 2025 and $123,107,116 in fiscal years 2023 through 2027.
How does Elusys Therapeutics Inc. rank among federal contractors?
Elusys Therapeutics Inc.'s parent company, Nighthawk Biosciences, Inc., ranked #9 in NAICS 325412, #10 in NAICS 3254 and #11 in PSC 6505 in FY2025.
What is Elusys Therapeutics Inc.'s most recent federal award?
Elusys Therapeutics Inc.'s most recent federal contract award is Anthim (OBILTOXAXIMAB) (75A50324C00006), from Office of the Assistant Secretary for Preparedness and Response, on May 1, 2024.
On GovTribe
See Elusys Therapeutics Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors